We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The first U.S. patients have been dosed in a clinical trial testing whether four experimental mRNA vaccine candidates can prevent infection with the virus that causes COVID-19 disease.
These are the findings of a study in mice led by researchers from NYU Langone Medical Center and its Perlmutter Cancer Center, and published online July 18 in Cell Reports.